论文部分内容阅读
目的:观察胰激肽原酶片治疗早期糖尿病肾病(DN)的临床效果。方法:将100例早期DN患者随机分为两组,每组50例。对照组给予常规治疗,观察组在常规治疗的基础上加用胰激肽原酶片。治疗3周后分别检测两组患者的肾功能和尿蛋白定量。结果:与治疗前比较,观察组治疗后血肌酐与尿白蛋白排泄率(UAER)均下降(P均<0.01)。观察组治疗后UAER下降优于对照组(P<0.01)。结论:胰激肽原酶片对早期DN有减少蛋白尿、改善肾功能的功效。
Objective: To observe the clinical effect of pancreatic kallikrein in the treatment of early diabetic nephropathy (DN). Methods: One hundred patients with early stage DN were randomly divided into two groups, 50 cases in each group. The control group was given routine treatment. The observation group was given pancreatic kallikrein on the basis of routine treatment. After 3 weeks of treatment, renal function and urinary protein were measured in two groups respectively. Results: Compared with before treatment, the serum creatinine and urinary albumin excretion rate (UAER) in observation group decreased after treatment (all P <0.01). The decrease of UAER in observation group was better than that in control group (P <0.01). Conclusion: Pancreatic kallikrein tablets have the effect of reducing proteinuria and improving renal function in early DN.